University of Turku, 20014 Turku, Finland.
J Clin Endocrinol Metab. 2012 Nov;97(11):4228-35. doi: 10.1210/jc.2012-1154. Epub 2012 Sep 11.
Aberrant estrogen synthesis and metabolism have been suggested to increase local estradiol (E2) concentration in endometriosis and thus to promote the growth of the lesions. However, tissue estrogen concentrations within the endometrium and different types of endometriosis lesions have not been described.
The aim of the study was to evaluate local E2 and estrone (E1) concentrations in the endometrium and different types of endometriosis lesions, and to correlate them with the expression of estrogen-metabolizing enzymes.
Patients with endometriosis (n = 60) and healthy controls (n = 16) participated in the study.
We measured serum and tissue concentrations of E2 and E1 as well as mRNA expression of the estrogen-metabolizing enzymes.
Endometrial or endometriotic intratissue E2 concentrations did not reflect the corresponding serum levels. In the proliferative phase, endometrial E2 concentration was five to eight times higher than in the serum, whereas in the secretory phase the E2 concentration was about half of that in the serum. Accordingly, a markedly higher E2/E1 ratio was observed in the endometrium at the proliferative phase compared with the secretory phase. In the endometriosis lesions, E2 levels were predominating over those of E1 throughout the menstrual cycle. Among the hydroxysteroid (17β) dehydrogenase (HSD17B) enzymes analyzed, HSD17B2 negatively correlated with the E2 concentration in the endometrium, and HSD17B6 was strongly expressed, especially in the deep lesions.
Endometrial or endometriotic tissue E2 concentrations are actively regulated by local estrogen metabolism in the tissue. Thus, the inhibition of local E2 synthesis is a valid, novel approach to reduce local E2-dependent growth of endometriotic tissue.
异常的雌激素合成和代谢被认为会增加子宫内膜异位症中的局部雌二醇(E2)浓度,从而促进病变的生长。然而,子宫内膜内的组织雌激素浓度和不同类型的子宫内膜异位症病变尚未被描述。
本研究旨在评估子宫内膜和不同类型的子宫内膜异位症病变中的局部 E2 和雌酮(E1)浓度,并将其与雌激素代谢酶的表达相关联。
本研究纳入了 60 名子宫内膜异位症患者(病例组)和 16 名健康对照者(对照组)。
我们测量了血清和组织中的 E2 和 E1 浓度以及雌激素代谢酶的 mRNA 表达。
子宫内膜或子宫内膜异位症组织内的 E2 浓度并不能反映相应的血清水平。在增殖期,子宫内膜中的 E2 浓度是血清中的五到八倍,而在分泌期,E2 浓度约为血清中的一半。相应地,在增殖期子宫内膜中观察到明显高于分泌期的 E2/E1 比值。在子宫内膜异位症病变中,E2 水平在整个月经周期中均高于 E1。在所分析的羟甾类(17β)脱氢酶(HSD17B)酶中,HSD17B2 与子宫内膜中的 E2 浓度呈负相关,而 HSD17B6 表达强烈,尤其是在深部病变中。
子宫内膜或子宫内膜异位症组织中的 E2 浓度是由组织内的局部雌激素代谢主动调节的。因此,抑制局部 E2 合成是减少子宫内膜异位症组织中局部 E2 依赖性生长的一种有效、新颖的方法。